Articles & Guides
Educational content covering peptide research, reconstitution guides, safety considerations, and more.
Retatrutide Beats Semaglutide in First Head-to-Head Diabetes Trial
Eli Lilly's triple agonist outperformed Ozempic on both blood sugar and weight in a Phase 3 comparison, but the stronger results came with more side effects.
Employers Pull Back on GLP-1 Coverage Heading Into 2027
As use of weight-loss drugs climbs, a share of employers are trimming or dropping coverage for 2027, citing cost.
Amylin Analogues Explained: Cagrilintide, Petrelintide, and the Satiety Pathway
Amylin is a satiety hormone distinct from GLP-1, and a new class of analogues is drawing research attention as a complement or alternative to incretin drugs.
Thymosin Alpha-1 and the Thymic Peptides: Immune-Modulation Research
A peptide derived from the thymus has a long research history in immune modulation, influencing T-cell and dendritic-cell activity.
KPV: The Anti-Inflammatory Tripeptide Derived From Alpha-MSH
A three-amino-acid fragment of alpha-MSH, KPV is studied for anti-inflammatory activity through mechanisms that point to NF-kB signaling.
Co-Reconstituting Peptide Blends: Handling Multi-Compound Vials
Blend vials hold more than one peptide at a fixed ratio, which changes how reconstitution math and concentration work compared with a single compound.
Traveling With Research Peptides: Cold-Chain, Flights, and Vial Stability
Keeping peptides stable on the move comes down to understanding the difference between powder and reconstituted solution, and avoiding heat and freezing.
Orforglipron Gets a Positive EMA Opinion, Nearing EU Approval
A key European scientific committee has recommended authorization for the oral small-molecule GLP-1, moving it a step closer to the EU market.
Novo Nordisk Will Discontinue Saxenda in the US
Novo is winding down its older daily weight-management injectable, framing the move as a portfolio decision rather than a safety issue.
Semaglutide's Patent Cliff in China and India Opens the Door to Generics
Key patent protection for semaglutide is expiring in two of the world's largest markets, setting the stage for lower-cost generic versions.
Glucagon/GLP-1 Dual Agonists: Survodutide, Mazdutide, and the Liver-Fat Rationale
Adding glucagon-receptor activation to a GLP-1 backbone is a research strategy aimed at energy expenditure and liver fat, with a built-in balancing act.
Kisspeptin: The Reproductive-Axis Peptide and What Research Shows
Encoded by the KISS1 gene, kisspeptin sits at the top of the reproductive hormone axis and acts as a master regulator of puberty and reproduction.
Nasal Spray Peptides: Preparation, Dosing Accuracy, and What Goes Wrong
Intranasal peptide preparations avoid injection but introduce their own handling and accuracy challenges that an insulin syringe does not have.
Sterile Technique for Multi-Dose Research Vials
A multi-dose vial is entered many times over its life, so aseptic technique at the stopper is what keeps its contents usable.
Survodutide's SYNCHRONIZE-2 Diabetes Results Land at EASD 2026
Phase 3 SYNCHRONIZE-2 results for survodutide in type 2 diabetes and obesity were presented at EASD 2026, extending the case for glucagon/GLP-1 dual agonists.
Retatrutide and Orforglipron: How to Read the Safety Data on the Next Wave
The compounds coming behind semaglutide and tirzepatide have thinner safety datasets by definition. What phase 2 actually tells you, why rare events stay hidden until after approval, and what that means for reading early trial results.
Is Retatrutide a Biologic? A Federal Appeals Court Weighs the Exclusivity Question
A federal appeals court heard arguments over whether retatrutide is a biologic or a conventional drug, a classification that sets its market-exclusivity period.
Research-Source GLP-1 Vials: Sourcing and Handling Risks Worth Understanding
Semaglutide and tirzepatide sold as research chemicals are a different product category from pharmacy-dispensed medication, with a different risk profile. What the sourcing risks actually are, from salt forms to sterility to label accuracy.
Petrelintide's Phase 3 ZUPREME Program Begins, Testing a Once-Weekly Amylin
The registrational Phase 3 ZUPREME program launched for petrelintide, a once-weekly amylin analogue, spanning three trials and roughly 7,000 participants.
Two Weight-Loss Pills Compared: Foundayo vs. the Wegovy Pill Ahead of EASD
At EASD 2026, Eli Lilly highlighted data positioning oral orforglipron as delivering superior weight loss and glucose reduction versus the oral semaglutide pill in type 2 diabetes.
Retatrutide's TRIUMPH-2 Diabetes Data Headline the Run-Up to EASD 2026
Retatrutide's TRIUMPH-2 study in type 2 diabetes showed up to about 20.8% weight loss and A1C reductions of up to 1.6% at 80 weeks, headed for presentation at EASD 2026.
Muscle Loss on GLP-1s: What the Body Composition Data Shows
A meaningful share of the weight lost on GLP-1 compounds is lean mass, and the DEXA substudies put numbers on it. What the trial data shows, why it matters, and what the research literature suggests about protecting muscle during rapid weight loss.
ATTAIN-MAINTAIN: Oral Orforglipron Holds Weight Loss After Switching From Injectables
In the ATTAIN-MAINTAIN trial, patients who switched from injectable GLP-1s to oral orforglipron showed superior maintenance of their weight loss versus comparator.
GLP-1 Safety Signals: Pancreatitis, Gallbladder Disease, and the Thyroid Warning
The serious adverse events attached to GLP-1 compounds are rare, but they have recognizable early patterns. What the trial data shows on pancreatitis, gallstones, and the rodent thyroid finding, and what warning signs look like.
Semaglutide Injection Safety: Site Rotation, Storage, and Missed Doses
Most problems with injectable GLP-1 compounds come from handling, not the molecule itself. Where to inject, how to rotate sites, how to store a vial, and what to do about a missed dose.
Retatrutide Data in Knee Osteoarthritis: Weight Loss Plus Pain Reduction
In the TRIUMPH program, retatrutide produced large weight loss alongside substantial reductions in knee osteoarthritis pain, raising questions about the link between the two.
Survodutide Normalizes Liver Fat in 61% of MASLD Patients in Phase 3
In the phase 3 SYNCHRONIZE-MASLD program, survodutide normalized liver fat in 61% of patients at 48 weeks, adding to the case for glucagon/GLP-1 dual agonists in liver disease.
Innovent Files High-Dose Mazdutide in China for Severe Obesity
Innovent filed a higher-strength 9 mg version of mazdutide, the first approved GLP-1/glucagon agonist for obesity, aimed at moderate-to-severe obesity in China.
Altimmune Launches PERFORMA, a Phase 3 MASH Trial of Pemvidutide
Altimmune began the PERFORMA Phase 3 trial testing pemvidutide, a GLP-1/glucagon dual agonist, in adults with MASH and moderate-to-advanced liver fibrosis.
Ascletis Begins US Phase 1 of ASC36, a Long-Acting Amylin Peptide
Ascletis Pharma launched two US Phase 1 studies after FDA clearance of its IND applications, including ASC36, a long-acting amylin receptor peptide agonist.
MBX 4291 Posts Early Phase 1 Data Supporting Once-Monthly Dosing
MBX Biosciences reported preliminary Phase 1 findings for MBX 4291, with early blinded data showing about 7% mean weight loss at eight weeks and support for monthly dosing.
UK Clears Foundayo (Orforglipron), Europe's First Oral GLP-1 Weight Pill
On August 10, 2026, the UK's MHRA authorized orforglipron under the brand Foundayo, making Britain the first country in Europe to approve the oral GLP-1 tablet.
Neurocrine Starts Phase 1 for NBIP-1968, a Triple-Agonist Obesity Peptide
Neurocrine Biosciences began a first-in-human Phase 1 study of NBIP-1968, a triple GLP-1/GIP/glucagon receptor agonist, entering the same class as retatrutide.
CagriSema Under FDA Review: A GLP-1/Amylin Combo Awaits a Late-2026 Decision
Novo Nordisk's CagriSema, pairing cagrilintide with semaglutide, is under FDA review with a decision anticipated by late 2026. It would be the first injectable GLP-1 plus amylin combination.
FDA's 503B Bulks-List Proposal on GLP-1s: Comment Period Closes
The FDA's proposal to permanently bar semaglutide, tirzepatide, and liraglutide from the 503B Bulks List reached the end of its public comment window on July 30, 2026.
Why Clinicians Are Wary of Compounded GLP-1s in 2026
Through 2026, clinicians raised mounting concerns about compounded GLP-1s, and the FDA issued dozens of warning letters over misleading marketing claims.
Semaglutide Misses in Alzheimer's: What the EVOKE and EVOKE+ Trials Showed
Novo Nordisk's phase 3 EVOKE trials tested oral semaglutide in early Alzheimer's and did not slow disease progression, though small biomarker shifts appeared.
Peptide Half-Lives: Why Some Compounds Are Dosed Daily and Others Weekly
Half-life is the reason a GLP-1 runs once a week while a growth hormone secretagogue gets split across the day. A plain guide to how long each common research peptide stays active.
GLOW and KLOW: What's Actually in the Popular Peptide Blends
The two blend names come up constantly in research discussions, usually without the ratios. Here is what each vial contains and what the published literature says about each component on its own.
Oral Peptides and Bioavailability: Why Capsule Research Doses Run So High
Digestive enzymes tear most peptide chains apart before they reach the bloodstream. That one fact explains why capsule research doses look nothing like injectable ones, and why some capsule compounds aren't peptides at all.
SS-31 (Elamipretide): The Peptide That Targets the Inner Mitochondrial Membrane
Elamipretide is one of the few research compounds with a precise molecular address: cardiolipin on the inner mitochondrial membrane. A look at the mechanism and where its clinical trial program stands.
AOD-9604: The Growth Hormone Fragment Studied for Fat Metabolism
AOD-9604 is a 15-amino-acid fragment of human growth hormone, built to isolate the fat-metabolism activity from the growth effects. Its human trial record is more complicated than most listings suggest.
BPC-157 Reaches a Controlled Trial: Phase 2 in Hamstring Injury Meets a Thin Evidence Base
A controlled Phase 2 study is testing BPC-157 in hamstring injuries, a rare step for a peptide whose human evidence remains strikingly limited despite decades of preclinical work.
Amgen's Once-Monthly MariTide Enters a Six-Trial Phase 3 Program
MariTide, Amgen's once-monthly peptide-antibody conjugate, moved into a sprawling six-study Phase 3 program spanning weight management, heart failure, and sleep apnea.
Tirzepatide's Liver Data: SYNERGY-NASH and the Pending MASH Decision
Tirzepatide's phase 2 SYNERGY-NASH results pointed to histological improvement in liver disease. An FDA decision on a MASH indication remained pending through 2026.
Novo Advances Amycretin, a GLP-1/Amylin Single Molecule, Into Phase 3
Novo Nordisk moved amycretin, a single molecule that hits both the GLP-1 and amylin receptors, into a global Phase 3 program testing injectable and oral forms.
The Oral Wegovy Pill, Six Months In: Real-World Uptake of 25 mg Semaglutide
Six months after launch, the first oral GLP-1 for chronic weight management is finding its footing. Its strict fasting-and-water protocol shapes how it is used day to day.
Foundayo Hits $50-a-Month Medicare Pricing as Oral GLP-1 Access Widens
Eli Lilly's oral pill Foundayo reached a roughly $50 monthly price for eligible Medicare Part D patients on July 1, 2026. The move widens access to the first oral small-molecule GLP-1.
Why 2026 Is the Year Peptides Went Mainstream
Google searches for peptides surged 30%+ in late 2025. TIME Magazine ran a cover feature. Northwestern University held a Grand Rounds on peptide therapy. A look at what drove the shift and where the attention has landed.
Semaglutide vs Tirzepatide vs Retatrutide: GLP-1, GLP-2, GLP-3 Compared
A head-to-head comparison of all three generations of GLP-based weight-loss peptides — mechanism, Phase 3 efficacy data, side effect profiles, and what the differences mean for research.
Retatrutide Phase 3 TRIUMPH-1 Results: 28.3% Weight Loss at 80 Weeks
Eli Lilly's May 2026 TRIUMPH-1 trial results place retatrutide ahead of every approved obesity drug in average weight reduction, with up to 30% body weight lost at the highest dose.
Semax vs Selank: The Cognitive Peptide Comparison
Both are Russian-developed nootropic peptides with clinical data behind them — but they work through entirely different mechanisms. A complete research comparison of Semax and Selank.
GHK-Cu: The Copper Peptide That Influences Over 4,000 Human Genes
GHK-Cu (copper peptide) modulates 31.2% of the human genome and has over four decades of clinical evidence. A detailed look at the gene expression data, skin research, and wound healing mechanisms.
The BPC-157 + TB-500 Stack: What Research Says About Combining Them
Called the 'Wolverine Stack' by the biohacker community, the BPC-157 + TB-500 combination has been one of the most discussed peptide pairings since 2023. The evidence for stacking them comes almost entirely from separate animal studies.
Injectable NAD+: What the 500mg Buffered Vial Research Actually Shows
NAD+ levels decline approximately 50% between ages 40 and 60. Injectable buffered NAD+ is one of the most discussed longevity interventions — here's what the evidence actually supports, and what it doesn't.
BPC-157 Human Trial Status: What the Evidence Actually Shows in 2026
By mid-2026, fewer than 30 people have been studied in published BPC-157 human research across three pilot studies. This is an accounting of the preclinical work and the small human trials behind it.
FDA Peptide Regulatory Update 2026: What Category 1 and Category 2 Mean
In February 2026, HHS announced that ~14 of 19 Category 2 peptides — including Semax, Selank, and potentially BPC-157 — would be moved to Category 1, reopening the compounding pharmacy pathway.
Bacteriostatic Water vs Sterile Water for Peptide Reconstitution: What's the Difference?
Using the wrong diluent is the most common reconstitution mistake. Here's exactly why bacteriostatic water is required for multi-dose research, what benzyl alcohol actually does, and when sterile water is appropriate.
Subcutaneous vs Intramuscular vs Intranasal: Which Peptide Delivery Route Is Best?
Route of administration determines bioavailability, onset speed, duration, and practical tolerability for every peptide on this site. A complete guide to understanding and choosing the right delivery method.
Peptide Cycling: On/Off Protocols for the Most Common Research Stacks
Should you cycle peptides? Which ones require breaks and which can be used continuously? A research-based guide to on/off protocols across every major peptide category.
How to Read a Peptide Certificate of Analysis (COA)
Independent testing finds purity discrepancies in roughly 15–20% of grey-market peptide COAs. Here's exactly what to look for, what the numbers mean, and how to spot a document that doesn't pass scrutiny.
Tesamorelin vs Ipamorelin vs CJC-1295: Choosing a GH Secretagogue Protocol
Three different growth hormone secretagogues, three different mechanisms, three different use cases. A complete comparison of the most studied GH-optimizing peptides and how to select and stack them.
PT-141 vs Melanotan II: Same Family, Very Different Research Profiles
PT-141 is FDA-approved. Melanotan II is not — and the differences between them explain why. A complete mechanistic comparison of two melanocortin peptides with overlapping origins but diverging research trajectories.
Complete Peptide Reconstitution Guide
Learn how to properly reconstitute lyophilized peptides with bacteriostatic water.
Managing GLP-1 Side Effects: Nausea, Constipation, and GI Discomfort
Nausea affects ~33–44% of GLP-1 users and is the primary reason people discontinue. The trial data explains why GI side effects happen and which titration approaches reduce them.
BPC-157: Research Overview
An in-depth look at the scientific research behind BPC-157 and its mechanisms.
Epithalon and Telomerase: The Science Behind the Longevity Claims
Epithalon is the most studied peptide for telomerase activation, with research spanning 40 years and a unique mechanistic rationale. The evidence is strongest in cell and animal work, thinner in the human trials.
Proper Peptide Storage
Maximize peptide stability with proper storage techniques and temperature control.
TB-500: Understanding Thymosin Beta-4
Explore the science behind TB-500 and its role in tissue repair research.
Peptide Safety Considerations
Important safety information and best practices for peptide research.
Choosing the Right Syringe for Peptides
A comprehensive guide to syringe types, gauges, and proper usage.
MOTS-c: The Mitochondrial Peptide That Mimics Exercise
MOTS-c is encoded within the mitochondrial genome itself — making it one of the few peptides with purely mitochondrial origin. A review of the exercise, insulin-sensitivity and lifespan research behind it.
Dihexa: The Synaptic Growth Factor Peptide That's 10 Million Times More Potent Than BDNF
Dihexa's claimed potency figure is real — but needs precise context to understand. An explanation of the HGF/c-Met mechanism, what the 10-million-times figure was measured against, and the limits of the data.
CagriSema: The Cagrilintide + Semaglutide Combination Protocol
CagriSema combines an amylin analog with a GLP-1 agonist in a single weekly injection. Phase 3 REDEFINE trial data shows ~22–25% weight loss — exceeding either agent alone. Here's how the dual mechanism works.